Asset
Zevotrelvir
Enanta Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05246878 | phase1 | completed | 2022-01-28 | 2022-07-20 | Enanta Pharmaceuticals, Inc | A Study of EDP-235 in Healthy Subjects |
| NCT05616728 | phase2 | completed | 2022-11-10 | 2023-02-08 | Enanta Pharmaceuticals, Inc | A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19 |
| NCT05594602 | phase1 | completed | 2022-10-06 | 2022-12-14 | Enanta Pharmaceuticals, Inc | Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects. |
| NCT05594615 | phase1 | completed | 2022-10-06 | 2022-11-04 | Enanta Pharmaceuticals, Inc | Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects |
FDA applications (0)
This company has no applications containing this asset.